Epidemiology of rheumatoid arthritis: genetic and environmental influences

Venetsanopoulou, Aliki I.; Alamanos, Yannis; Aa, Drosos

doi:10.1080/1744666x.2022.2106970

Cited by 44 publications

(29 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that RA is a common inflammatory arthritis with an increasing prevalence in many countries. ( Venetsanopoulou et al, 2022 ). However, treatment options for many of these diseases remain inadequate for most patients, and progress in developing new treatments has been slow.…”

Section: Discussionmentioning

confidence: 99%

Detecting potential mechanism of vitamin D in treating rheumatoid arthritis based on network pharmacology and molecular docking

Luo

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Aim: Vitamin D plays a vital role in Rheumatoid arthritis (RA). However, the mechanism of vitamin D and rheumatism is still unclear. Therefore, a strategy based on network pharmacology and molecular docking was used to explore the mechanism of vitamin D and RA.Methods: The targets of RA were obtained from the GeneCards database and Therapeutic Targets Database, and the targets of vitamin D were obtained from the Drugbank database and STITCH database. Next, overlapping genes were identified by Venny, and further Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and molecular docking analyses were performed.Results: A total of 1,139 targets of RA and 201 targets of vitamin D were obtained. A total of 76 overlapping genes were identified by Venny. The enrichment analysis showed that cell proliferation, immune response, and apoptotic process were the critical biological processes of vitamin D in treating RA. Antifolate resistance, osteoclast differentiation, and the nuclear factor-kappa B (NF-κB) signalling pathway are fundamental mechanisms of vitamin D in treating RA. According to further molecular docking, ALB, TNF, CASP3, and TP53 may be important punctuation points or diagnostic markers for future RA treatment.Conclusion: By analysing overlapping genes of diseases and drugs, this study confirmed that ALB, TNF, CASP3, and TP53 may be essential markers or diagnostic markers for future RA treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Detecting potential mechanism of vitamin D in treating rheumatoid arthritis based on network pharmacology and molecular docking

Luo

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…1,2 The prevalence of RA is 0.5-1% worldwide, with women suffering from the disease approximately four times more often than men. 3 The main pathological manifestations of RA are chronic inflammation of the synovial membrane, formation of vascular opacities, and persistent inflammation that damages articular cartilage, ligaments and tendons, resulting in joint deformity and loss of function. 4,5 These complications can be accompanied by systemic symptoms such as weight loss, hypothermia and fatigue.…”

Section: Introductionmentioning

confidence: 99%

Integrated Network Pharmacology and Experimental Validation Approach to Investigate the Mechanisms of Stigmasterol in the Treatment of Rheumatoid Arthritis

Xie¹,

Ye²,

Guo³

et al. 2023

DDDT

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints associated with systemic comorbidities. Sinomenium acutum is regarded as an effective traditional Chinese medicine (TCM) for the treatment of RA. Materials and Methods: Based on network pharmacology and Gene Expression Omnibus (GEO) database, 33 RA-related differentially-expressed genes (DEGs) targeting active compounds of Sinomenium acutum were initially screened in our investigation. Results: Gene Ontology (GO) and Kyoto encyclopaedia of genes and genome (KEGG) analyses found the important involvement of these DEGs in osteoclast differentiation, and finally 5 core DEGs, including NCF4, NFKB1, CYBA, IL-1β and NCF1 were determined through protein-protein interaction (PPI) network. We also identified the related active component of Sinomenium acutum include Stigmasterol. Finally, in order to experimentally verify these results, a rat model of collagen-induced arthritis (CIA) was established, and subsequently treated with Stigmasterol solution. Conclusion: Similar to the healing effect of Indomethacin, Stigmasterol was observed to reduce the levels of inflammatory factors (IL-6 and IL-1β) and osteoclast differentiation-related factors (RANKL, ACP5 and Cathepsin K), which can also reduce the arthritis index score and alleviate the degree of pathological injury of rat ankle joints. The predictions and experimental data uncover the involvement of Stigmasterol, an active component of Sinomenium acutum, in regulation of osteoclast differentiation, exerting great medicinal potential in the treatment of RA.

show abstract

“…Rheumatoid arthritis (RA) is a chronic autoimmune disease that causes joint inflammation, swelling, stiffness, and pain 1 . Generally, RA is more prevalent in females than males, and older age, obesity, family disease history, and smoking are also risk factors for this disease 2–4 . In terms of the treatments for RA patients, conventional synthetic disease‐modifying antirheumatic drugs (csDMARD) are the recommended treatment options; 5,6 ; however, these drugs usually need a long period of time to become effective, and the treatment response to these drugs may be not satisfactory 7,8 .…”

Section: Introductionmentioning

confidence: 99%

“…1 Generally, RA is more prevalent in females than males, and older age, obesity, family disease history, and smoking are also risk factors for this disease. [2][3][4] In terms of the treatments for RA patients, conventional synthetic diseasemodifying antirheumatic drugs (csDMARD) are the recommended treatment options; 5,6 ; however, these drugs usually need a long period of time to become effective, and the treatment response to these drugs may be not satisfactory. 7,8 In this case, biological (b) DMARD are provided to achieve rapid relief of the symptoms; meanwhile, this treatment has the advantage of inhibiting the radiographic progression of RA.…”

Section: Introductionmentioning

confidence: 99%

Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients

Yang,

Wu,

Tian

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Aim Our previous study discovered that cell division control protein 42 (CDC42) correlated with decreased disease activity and risk of developing rheumatoid arthritis (RA), along with repressed T helper type 17 cell differentiation. This study aimed to further estimate the longitudinal change of serum CDC42 and its association with treatment outcomes to tumor necrosis factor inhibitor (TNFi) in RA. Methods CDC42 was detected in serum by ELISA at week (W)0, W6, W12, and W24 in 88 RA patients undergoing TNFi treatment, and after enrollment in 20 disease controls (DCs) and 20 healthy controls (HCs). Results CDC42 was lower in RA patients compared with DCs and HCs (both p < .001); meanwhile, it negatively related to C‐reactive protein (p = .011) and DAS28 score (p = .006). Regarding TNFi type, 40.9%, 33.0%, 17.0%, and 9.1% of patients received adalimumab, etanercept, golimumab, and infliximab, respectively. Notably, CDC42 was increased from W0 to W24 in RA patients receiving TNFi treatment (p < .001), also in patients receiving adalimumab (p < .001), etanercept (p < .001), golimumab (p < .001), and infliximab (p = .001). Furthermore, CDC42 at W24 was higher in patients with a clinical response to TNFi treatment compared with those without (p = .023); CDC42 at W12 (p = .027) and W24 (p = .002) was elevated in patients with clinical low disease activity in response to TNFi treatment versus those without; whereas CDC42 at W12 (p = .074) and W24 (p = .068) only showed an increasing trend in patients with clinical remission with TNFi treatment, but did not achieve statistical significance. Conclusion Circulating CDC42 is elevated during TNFi administration; its increase reflects good 24‐week TNFi treatment responses in RA patients.

show abstract

Epidemiology of rheumatoid arthritis: genetic and environmental influences

Cited by 44 publications

References 102 publications

Detecting potential mechanism of vitamin D in treating rheumatoid arthritis based on network pharmacology and molecular docking

Detecting potential mechanism of vitamin D in treating rheumatoid arthritis based on network pharmacology and molecular docking

Integrated Network Pharmacology and Experimental Validation Approach to Investigate the Mechanisms of Stigmasterol in the Treatment of Rheumatoid Arthritis

Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients

Contact Info

Product

Resources

About